top of page
Topic: Thoracic rare cancers
CPGs graded Strong
Locatelli-Sanchez M, Foucher P, Pérol M, Scherpereel A, Zalcman G, on behalf of the editing committee of Auvergne Rhône-Alpes Guidelines in Thoracic Oncology and MESOCLIN network. [Guidelines on Malignant Mesothelioma of the pleura: 2019 Update]. ARISTOT/MESOCLIN; 2019 [French]. https://ressources-aura.fr/wp-content/uploads/2018/12/MM_2019_VDEF.pdf 
Van Zandwijk N., Clarke C., Henderson, D et al (2013). Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3886874/pdf/jtd-05-06-E254.pdf
CPGs graded Moderate
Girard N, Besse B, Barlesi F et al. (2016). Tumeurs épithéliales thymiques - Référentiel du réseau Tumeurs Thymiques et cancers.https://ressources-aura.fr/wp-content/uploads/2018/12/Thymomes_2016.pdf
HAS/ INCA (2013). Recommandations nationales -Guide du Parcours de soins : Mésothéliome pleural malin (Pleural mesothelioma). 
https://www.has-sante.fr/portail/upload/docs/application/pdf/2013-10/guide_mesotheliome_pleural_malin_final_web_091013.pdf
N. Girard, E. Ruffini et al. (2015). Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. https://academic.oup.com/annonc/article-pdf/26/suppl_5/v31/6675007/mdv199.pdf  
P. Baas, D. Fennell, K. M. Kerr et al. (2015). Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. https://academic.oup.com/annonc/article-pdf/26/suppl_5/v31/6675007/mdv199.pdf
Husain AN, Colby TV, Ordonez NG et al. (2017). Guidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the consensus statement. https://www.archivesofpathology.org/doi/pdf/10.5858/arpa.2017-0124-RA
Hjerpe A, Valeria A, Bedrossian CWM et al. (2015). Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma. https://www.karger.com/Article/Pdf/377697
Unbenannt.JPG

Work Package 6

_project_management_standards.jpg

Tasks of work package 6

​

  • Map available clinical practice guidelines (CPGs) at the European level on all families of rare cancers and identify gaps

  • Quality evaluation of existing guidelines for rare cancer subtypes  

​

The JARC Work Package 6 maintains this website to share the results of quality evaluation of existing CPGs at European local and national level on rare cancers with partners involved in the EU JARC Project. However, the JARC Work Package 6 does not accept any responsibility or obligation of any kind whatsoever with regard to the information contained on this site.

The  JARC WP 6 Website contains links to other websites.

Not having control over the content of these third-party websites, no responsibility is assumed for their policies or practices.

Therefore, please review the privacy policies of these third-party websites.

Tasks of work package 6

​​

  • Open issues about implementation of CPGs at the local level and their interface with reimbursement systems

  • Work out solutions on how to assess the implementation of CPGs in the context of ERNs and national clinical collaborative networks

bottom of page